Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GuARD trial of GR1014 cutaneous gel against radiation dermatitis
ISRCTN61697120Phase 2Completed
- Sponsor
- Graegis Pharmaceuticals
- Start
- Jul 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised trial of GR1014 in radiodermatitis, sponsored by Graegis Pharmaceuticals. Started Jul 2024; status: completed.
02
Drugs
GR1014
03
Conditions
radiodermatitis
Beyond the preview
Go deeper on ISRCTN61697120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61697120.